CHICAGO — Danny Rischin, MBBS, FRACP, MD, director of the division of cancer medicine and head of the medical oncology department at Peter MacCallum Cancer Centre in Australia, spoke with HemOnc Today at ASCO Annual Meeting about research into cemiplimab.
Cemiplimab (REGN2810; Regeneron, Sanofi) is a monoclonal antibody that targets PD-1.
A phase 2 study assessed cemiplimab for patients with metastatic cutaneous squamous cell carcinoma, a malignancy for which no approved agents exist.
The study results — presented at ASCO and simultaneously published in The New England Journal of Medicine — showed nearly half (47.5%) of patients achieved an objective response. Those responses appeared rapid and durable, Rischin said. Cemiplimab also appeared well tolerated, he added.
“Cemiplimab demonstrated very impressive activity with sustained responses, and I think it’s likely to represent a new standard of care,” Rischin told HemOnc Today.